06 Dec Lavipharm Celebrates Milestones and Opens Trading Session at Athens Exchange
Paiania, 6 December 2023 – Marking a remarkable year since its successful Share Capital Increase, Lavipharm, the sole Greek pharmaceutical company listed on the Athens Stock Exchange, proudly commenced today’s trading session. At this special event held at the Athens Exchange, Telemaque Lavidas, Executive Board Member, rang the traditional “bell” opening the session, surrounded by Lavipharm’s Board members, management team, company executives, and partners instrumental in the project’s success.
In his welcome address, Athens Exchange Group CEO, Yiannos Kontopoulos, lauded Lavipharm’s triumph as a challenging bet well-won: “The project’s success reflects investor confidence in Lavipharm, laying a solid foundation for its growth and further strengthening its position both within Greece and internationally. A year after the share capital increase, Lavipharm’s market capitalization exceeds EUR 110 million, and its share price has surged by approximately 100%. With the same enthusiasm that we welcome every new company to the Stock Exchange, we equally warmly embrace every successful endeavor of any listed company as Lavipharm. The persistent and substantial efforts of every company to implement its investment plan deserve and will always have our unwavering support.”
Addressing the event, Mr. Lavidas spoke about Lavipharm’s success story: “A year ago, we shared with the investment community our challenges along with our five-year plan. One year later, we have managed to outperform our plan, our shares are traded in the Main Market and have been included in both the ESG index and FTSE Russell Micro Cap index. Our performance is the result of a clear strategy, seamless execution, talented people’s hard work, and our determination to reach the top. Lavipharm is going through one of the most productive periods in its history”, concluded Mr. Lavidas in an atmosphere of emotion and enthusiasm.
Lavipharm boasts a rich legacy in the Greek pharmaceutical industry, having been established 112 years ago and listed on the Athens Exchange since 1995. Transdermal drug delivery technology serves as one of Lavipharm ‘s core competitive advantages, operating one of the few manufacturing sites worldwide.
###
